According to results from a recent phase II study, most patients with drug-resistant, true #extramedullary #myeloma responded to dual treatment with #talquetamab plus #teclistamab, with researchers observing a 61% PFS and 74% OS at 12 months: https://ow.ly/q6gI50YpblV #MMsm
#HemeSky #MedSky

🩸🔬 Today’s questions!

Swipe to see the answers and their explanations!

#MultipleMyeloma #MajesTEC3 #Teclistamab #BispecificAntibodies #StepUpDosing #Immunotherapy #IVIG #HematologyOncology #Oncology #MedEd #ClinicalTrials #HEMEHUB

🩸Facts about Multiple Myeloma:

Frontline Integration

#MultipleMyeloma #Hematology #BispecificAntibodies #StemCellTransplant #ASCT #BsAbs #MRD #ClinicalTrials #Elranatamab #Teclistamab #MajesTEC4 #MajesTEC5 #HemOnc #HEMEHUB

🩸Today’s question highlights the role of soluble BCMA levels in predicting response to teclistamab therapy.

See the answer and explanation on the next slide!

#MultipleMyeloma #Hematology #HemeOnc #MedEd #BCMA #Teclistamab #BispecificAntibodies #HEMEHUB #Immunotherapy #ClinicalTrials

🩸Facts about Multiple Myeloma:

Treatment Sequencing and Combinations

#MultipleMyeloma #Hematology #MedEd #HEMEHUB #Daratumumab #BispecificAntibodies #Teclistamab #IMiDs #Lenalidomide #Pomalidomide #Carfilzomib #Immunotherapy #Oncology

🩸Facts about Multiple Myeloma:

Resistance and Biomarkers

#Hematology #MultipleMyeloma #MedEd #Immunotherapy #BCMA #BsAbTherapy #Teclistamab #ClinicalResearch #ClinicalInsights #HematologyEducation #HEMEHUB

🩸📊Today’s question highlights long-term outcomes from the MajesTEC-3 trial.

See the answer and explanation on the next slide!

#MultipleMyeloma #MedEd #Hematology #Teclistamab #Daratumumab #BispecificAntibodies #ClinicalTrials #HemeOnc #MedEd #MajesTEC3 #HEMEHUB

🩸 Today’s question focuses on combination therapy evaluated in the MajesTEC-3 trial for relapsed/refractory multiple myeloma (RRMM).

See the answer and explanation on the next slide!

#MultipleMyeloma #Teclistamab #Pomalidomide #Daratumumab #Elranatamab #Carfilzomib #Talquetamab #Hematology

🩸Facts about Multiple Myeloma:

Adverse Events and Management

#CRS #ICANS #Neurotoxicity #Neutropenia #Teclistamab #MajesTEC3 #Immunotherapy #Tocilizumab #Hematology #RareDiseases #BloodDisorders #ClinicalInsights #MedEd #HEMEHUB

🩸 More insights on clinical efficacy and survival outcomes in Multiple Myeloma

#MultipleMyeloma #HemeOnc #Hematology #BispecificAntibodies #Linvoseltamab #Teclistamab #Talquetamab #ClinicalTrials #HEMEHUB #MedEd

🩸Facts about Multiple Myeloma:

Clinical Efficacy and Survival Outcomes

#MultipleMyeloma #BispecificAntibodies #Immunotherapy #Teclistamab #Elranatamab #Daratumumab #ClinicalTrials #Oncology #HematologicMalignancies #CancerTherapy #HEMEHUB

🩸Facts about Multiple Myeloma:

Bispecific Antibodies (BsAbs) – Mechanism and Approval

#MultipleMyeloma #RRMM #Hematology #HemOnc #BispecificAntibodies #BsAbs #Immunotherapy #CD3 #BCMA #Teclistamab #Elranatamab #Linvoseltamab #MedEd

Résultats #Majestec_3, le Dr Mateos a présenté le #LBA_6 : Étude randomisée de phase 3 du #Teclistamab plus #Daratumumab versus choix de l’investigateur entre dara et #Dexaméthasone avec #Pomalidomide ou #Bortézomib (#DPd/#DVd) chez des patients atteints de #MyélomeMultiple R/R

MajesTEC-3 supports teclistamab–daratumumab for relapsed/refractory multiple myeloma Phase 3 trial data show a significant improvement in progression-free survival with use of teclistamab plus daratumumab for patients with relapsed or refractory multiple myeloma.

From #ASH2025 - Phase 3 trial data show a significant improvement in progression-free survival with use of #teclistamab plus #daratumumab for patients with relapsed or refractory #MultipleMyeloma.

👉 buff.ly/7bKRL6f

#OncSky

Antibody-based combination therapy with #teclistamab and #daratumumab was shown to be highly effective in elderly patients with newly diagnosed #MultipleMyeloma #MMsm, producing a VGPR or better in 79% of patients and MRD negativity in 100% at six months: https://ow.ly/KQKn50XMHAW
#HemeSky #MedSky

Un nouvel espoir pour les patients atteints de myélome multiple - ON HEALTH Johnson & Johnson vient d'annoncer des résultats prometteurs pour une nouvelle immunothérapie contre le myélome multiple.

J&J vient de présenter des résultats prometteurs dans le #MyélomeMultiple 🩸

L’étude de phase 2 #MajesTEC_5 a évalué une association de 2 💊, le #Teclistamab & #Daratumumab & #Hyaluronidase, en 1ère ligne chez des patients éligibles à une #GreffeDeMoelle

on-health.tv/un-nouvel-es...

Significant Progress in Treating Relapsed Refractory Multiple Myeloma with Tec-Dara Combination Therapy A recent trial has revealed that the Tec-Dara combination therapy significantly outperforms standard treatments in relapsed refractory multiple myeloma, offering new hope to patients.

Significant Progress in Treating Relapsed Refractory Multiple Myeloma with Tec-Dara Combination Therapy #USA #Orlando #Multiple_Myeloma #Daratumumab #Teclistamab

Impact-AL: A phase 2 clinical trial of teclistamab and daratumumab in previously untreated AL amyloidosis Background and Significance: Systemic immunoglobulin light chain (AL) amyloidosis remains a challenging disease, with current frontline regimens faili…

#teclistamab and #daratumumab as the first treatment for people with a new diagnosis of AL-amyloidosis. Details via #ASH25 (2/2) clinicaltrials.gov/study/NCT071...

Inderdaad, al zijn er ook al geluiden dat #TECLISTAMAB misschien beter werkt dan #daratumumumab. Maar zou mooi zijn als het in die richting wordt gezocht idd. Reset auto immuun problematiek.

Teclistamab Shows Promising Effectiveness for Japanese Myeloma Patients in Long-Term Study A long-term follow-up study on teclistamab shows high response rates and prolonged effects in Japanese patients with refractory multiple myeloma.

Teclistamab Shows Promising Effectiveness for Japanese Myeloma Patients in Long-Term Study #Japan #Tokyo #Multiple_Myeloma #Teclistamab #Janssen_Pharmaceuticals

New Research from MD Anderson Shows that Teclistamab is Safe and Effective for Older Patients with RRMM - OncoDaily New Research from MD Anderson Shows that Teclistamab is Safe and Effective for Older Patients with RRMM / cancer, Hans Lee, MD Anderson Cancer Center, MM,

New Research from MD Anderson Shows that Teclistamab is Safe and Effective for Older Patients with RRMM
@mdanderson.bsky.social

oncodaily.com/insight/tecl...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #RRMM #MultipleMyeloma #Teclistamab #MDAnderson

Teclistamab-Induced Remission in Refractory Systemic Lupus Erythematosus | NEJM A woman with aggressive refractory systemic lupus erythematosus was treated with a short course of the bispecific antibody teclistamab (anti–B-cell maturation antigen and anti-CD3) and had a drug-...

ReadingRheum🛋️ Notes:

#Teclistamab 😋takes a "BiTE" out of Refractory SLE 🦋➡️🥄CD3-TCR,🍴BCMA

Will this turn the C-ART around?🤔

www.nejm.org/doi/10.1056/...

Watch as @ireneghobrial.bsky.social @danafarber.bsky.social dives into groundbreaking insights from longitudinal single-cell studies & #teclistamab outcomes at #ASH24 🎥

Don't miss this #VJHemOnc interview 👉 tinyurl.com/3u7dkrhn

@ash-hematology.bsky.social #MultipleMyeloma #MMsm

In my continuous search for treatments, I constantly come up against glass walls. I can see the treatment options out there, but either they are far too expensive or virtually inaccessible for my condition. #Sjogrens #daratumumab #CART #teclistamab